Portland, OR -- (SBWire) -- 07/04/2018 --The global anti-inflammatory market is expected to garner $106.1 billion by 2020, registering a CAGR of 5.9% during the period 2015-2020. The anti-inflammatory biologic segment held 3/5th of overall market in 2014. The Asia Pacific market would exhibit the highest CAGR of 8.5% during the forecast period.

Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells and heal injured tissues.

Get sample copy of this report @ https://www.alliedmarketresearch.com/request-sample/286

Sometimes, the body defense system inappropriately triggers inflammation against its own cells, resulting in incurable inflammatory autoimmune diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD).

According to World Health Organization (WHO), approximately 235 million people suffer from asthma in the world. Symptomatic relief during the inflammation provides relief to the patients suffering from inflammatory autoimmune diseases. Although there are multiple anti-inflammatory drugs approved in the market, there is an indispensable need for better and novel anti-inflammatory therapeutics with lesser side effects and better efficacy.

Make purchase enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/286

In developed economies, such as North America and Europe, branded drugs are preferred over generics whereas there has been a reverse trend in developing economies. This is evident from the fact that about 50% of the anti-inflammatory biologics market has its presence in the North America, whereas, Asia Pacific and LAMEA collectively accounted for 35% share in NSAIDs market as compared to about just 25% share of the branded biologics market in 2014.

Companies are adopting drug pipeline development and product launch as key strategies to overcome patent expiries of existing drugs and gain additional market share. Key companies profiled in the report are Pfizer Inc., Abbvie Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc. Novartis, F. Hoffman La Roche AG, Eli Lily and Company, AstraZeneca PLC. and Amgen.

Have questions? Speak with our analyst @ https://www.alliedmarketresearch.com/connect-to-analyst/286

Key findings of Anti-inflammatory Therapeutics Market:

- Arthritis indication was the major revenue generating segment in the global anti-inflammatory therapeutics market in 2014 followed by respiratory diseases.

- Psoriasis segment is the projected to grow at a CAGR of 8.1%, fastest among all.

- North America would continue to lead the market through 2020, currently accounts for about half of the global revenue.

- The U.S. accounted for about 5/6thof the North America anti-inflammatory therapeutics market revenue in 2014.

- Asia-Pacific is projected to be the fastest growing market.